PDCD1 and Miyoshi myopathy: Recent study showed that pembrolizumab (anti-PD-1) in combination with belapectin (Galectin-3 Inhibitor) significantly enhanced the activation of effector memory T cells and the percentage of effector memory T cell proliferation in MM patients.